Venenum BioDesign MGAT2 inhibitor

Venenum BioDesign is developing a series of small-molecule inhibitors targeting monoacylglycerol acyltransferase 2 (MGAT2), also known as MOGAT2, for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). MGAT2 is an enzyme primarily expressed in the small intestine and liver, where it plays a critical role in the absorption of dietary fat and the homeostasis of triglycerides. By inhibiting MGAT2 activity, these compounds aim to modulate lipid metabolism and reduce hepatic fat accumulation. The lead series, which includes substituted phenylsulfonamides, has demonstrated potency against both human and mouse MGAT2 with high selectivity over the related enzyme diacylglycerol O-acyltransferase 1 (DGAT1). The program is currently in the preclinical lead optimization stage.

Other names

MOGAT2 inhibitorMOGAT-2 inhibitorMOGAT 2 inhibitorsubstituted phenylsulfonamides